Michael Sumner
Chief Tech/Sci/R&D Officer chez INOVIO PHARMACEUTICALS, INC.
Fortune : 40 488 $ au 31/03/2024
Profil
Michael Sumner is currently the Chief Medical Officer at Inovio Pharmaceuticals, Inc. and a Member at The Royal College of Physicians.
Previously, he held positions such as Senior Director-Medical Affairs at Aventis Behring, Executive Director-Medical Affairs at Novo Nordisk Pharmaceuticals Pty Ltd., Vice President-Clinical & Medical Affairs at Shire Regenerative Medicine, Inc., and Medical Manager at Novartis Pharmaceuticals UK Ltd.
From 2013 to 2022, he served as the Chief Medical Officer at Orexo AB.
Dr. Sumner holds a doctorate degree from the University of London and an MBA from Henley Management College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/02/2024 | 2 917 ( 0,01% ) | 40 488 $ | 31/03/2024 |
Postes actifs de Michael Sumner
| Sociétés | Poste | Début |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 27/06/2022 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Anciens postes connus de Michael Sumner
| Sociétés | Poste | Fin |
|---|---|---|
| OREXO AB | Chief Tech/Sci/R&D Officer | 26/10/2022 |
Shire Regenerative Medicine, Inc.
 Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Chief Tech/Sci/R&D Officer | - |
Novo Nordisk Pharmaceuticals Pty Ltd.
 Novo Nordisk Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharmaceuticals Pty Ltd. manufactures pharmaceuticals for diabetes care. The company is headquartered in Baulkham Hills, Australia. | Chief Tech/Sci/R&D Officer | - |
| Aventis Behring | Chief Tech/Sci/R&D Officer | - |
Novartis Pharmaceuticals UK Ltd.
 Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Corporate Officer/Principal | - |
Formation de Michael Sumner
| University of London | Doctorate Degree |
| Henley Management College | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OREXO AB | Health Technology |
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Health Technology |
Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Health Technology |
| Aventis Behring | Health Technology |
Novo Nordisk Pharmaceuticals Pty Ltd.
Novo Nordisk Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharmaceuticals Pty Ltd. manufactures pharmaceuticals for diabetes care. The company is headquartered in Baulkham Hills, Australia. | Health Technology |
